Araujo A, Tavares N, Faria A, Gomes R, Carvalho Mendonca J, Parente B
Curr Oncol. 2023; 30(2):1529-1537.
PMID: 36826078
PMC: 9954894.
DOI: 10.3390/curroncol30020117.
Mosa A, Rana M, Islam H, Hossain A, Yoo I
JMIR Mhealth Uhealth. 2021; 9(12):e27024.
PMID: 34860677
PMC: 8686466.
DOI: 10.2196/27024.
McKenzie E, Zaki P, Raman S, Olson R, McFarlane T, DeAngelis C
Support Care Cancer. 2019; 27(3):783-791.
PMID: 30607675
DOI: 10.1007/s00520-018-4586-2.
Hsu J, Donnelly J, Moore J, Meneses K, Williams G, Wang H
Am J Emerg Med. 2018; 36(11):2038-2043.
PMID: 29573899
PMC: 6988579.
DOI: 10.1016/j.ajem.2018.03.025.
Puri S, Hyland K, Weiss K, Bell G, Gray J, Kim R
Support Care Cancer. 2018; 26(8):2911-2918.
PMID: 29546524
PMC: 6200138.
DOI: 10.1007/s00520-018-4120-6.
Stability of azasetron-dexamethasone mixture for chemotherapy-induced nausea and vomiting administration.
Fang B, Chen F, Zhu D, Guo J, Wang L
Oncotarget. 2018; 8(63):106249-106257.
PMID: 29290945
PMC: 5739730.
DOI: 10.18632/oncotarget.22174.
Comparative safety and effectiveness of serotonin receptor antagonists in patients undergoing chemotherapy: a systematic review and network meta-analysis.
Tricco A, Blondal E, Veroniki A, Soobiah C, Vafaei A, Ivory J
BMC Med. 2016; 14(1):216.
PMID: 28007031
PMC: 5180412.
DOI: 10.1186/s12916-016-0761-9.
Impact of adherence to antiemetic guidelines on the incidence of chemotherapy-induced nausea and vomiting and quality of life.
Abunahlah N, Sancar M, Dane F, Ozyavuz M
Int J Clin Pharm. 2016; 38(6):1464-1476.
PMID: 27796777
DOI: 10.1007/s11096-016-0393-3.
2016 Updated MASCC/ESMO Consensus Recommendations: Controlling nausea and vomiting with chemotherapy of low or minimal emetic potential.
Olver I, Ruhlmann C, Jahn F, Schwartzberg L, Rapoport B, Rittenberg C
Support Care Cancer. 2016; 25(1):297-301.
PMID: 27572335
DOI: 10.1007/s00520-016-3391-z.
Management of acute and delayed chemotherapy-induced nausea and vomiting: role of netupitant-palonosetron combination.
Janicki P
Ther Clin Risk Manag. 2016; 12:693-9.
PMID: 27194913
PMC: 4859423.
DOI: 10.2147/TCRM.S81126.
Control of nausea with palonosetron versus granisetron, both combined with dexamethasone, in patients receiving cisplatin- or anthracycline plus cyclophosphamide-based regimens.
Kubota K, Saito M, Aogi K, Sekine I, Yoshizawa H, Yanagita Y
Support Care Cancer. 2016; 24(9):4025-33.
PMID: 27129842
PMC: 4967099.
DOI: 10.1007/s00520-016-3203-5.
Controlling chemotherapy-induced nausea requires further improvement: symptom experience and risk factors among Korean patients.
Rha S, Park Y, Song S, Lee C, Lee J
Support Care Cancer. 2016; 24(8):3379-89.
PMID: 26984242
DOI: 10.1007/s00520-016-3146-x.
Clinical Practices and Outcomes on Chemotherapy-Induced Nausea and Vomiting Management in South Korea: Comparison with Asia-Pacific Data of the Pan Australasian Chemotherapy Induced Emesis Burden of Illness Study.
Lee M, Cho E, Oh S, Ahn J, Lee J, Thomas B
Cancer Res Treat. 2016; 48(4):1420-1428.
PMID: 26875197
PMC: 5080826.
DOI: 10.4143/crt.2015.309.
Antiemetic medication for prevention and treatment of chemotherapy-induced nausea and vomiting in childhood.
Phillips R, Friend A, Gibson F, Houghton E, Gopaul S, Craig J
Cochrane Database Syst Rev. 2016; 2:CD007786.
PMID: 26836199
PMC: 7073407.
DOI: 10.1002/14651858.CD007786.pub3.
Efficacy, tolerability, and safety of cannabinoids for chemotherapy-induced nausea and vomiting--a systematic review of systematic reviews.
Tafelski S, Hauser W, Schafer M
Schmerz. 2016; 30(1):14-24.
PMID: 26787227
DOI: 10.1007/s00482-015-0092-3.
Management of Chemotherapy Induced Nausea and Vomiting in Patients on Multiday Cisplatin Based Combination Chemotherapy.
Ranganath P, Einhorn L, Albany C
Biomed Res Int. 2015; 2015:943618.
PMID: 26425563
PMC: 4573879.
DOI: 10.1155/2015/943618.
Impact and management of chemotherapy/radiotherapy-induced nausea and vomiting and the perceptual gap between oncologists/oncology nurses and patients: a cross-sectional multinational survey.
Vidall C, Fernandez-Ortega P, Cortinovis D, Jahn P, Amlani B, Scotte F
Support Care Cancer. 2015; 23(11):3297-305.
PMID: 25953380
PMC: 4584113.
DOI: 10.1007/s00520-015-2750-5.
Aprepitant as prophylaxis of chemotherapy-induced nausea and vomiting in anthracyclines and cyclophosphamide-based regimen for adjuvant breast cancer.
Meattini I, Francolini G, Scotti V, De Luca Cardillo C, Cappelli S, Meacci F
Med Oncol. 2015; 32(3):80.
PMID: 25698536
DOI: 10.1007/s12032-015-0535-9.
Comparison between the antiemetic effects of palonosetron and granisetron in breast cancer patients treated with anthracycline-based regimens.
Ohzawa H, Miki A, Hozumi Y, Miyazaki C, Sagara Y, Tanaka Y
Oncol Lett. 2014; 9(1):119-124.
PMID: 25435944
PMC: 4246639.
DOI: 10.3892/ol.2014.2640.
Professional educational needs for chemotherapy-induced nausea and vomiting (CINV): multinational survey results from 2388 health care providers.
Van Laar E, Desai J, Jatoi A
Support Care Cancer. 2014; 23(1):151-7.
PMID: 25015057
PMC: 4291310.
DOI: 10.1007/s00520-014-2325-x.
